PH26714A - Novel human TNF polypeptide mutants and DNAs encoding said mutants - Google Patents

Novel human TNF polypeptide mutants and DNAs encoding said mutants Download PDF

Info

Publication number
PH26714A
PH26714A PH35431A PH35431A PH26714A PH 26714 A PH26714 A PH 26714A PH 35431 A PH35431 A PH 35431A PH 35431 A PH35431 A PH 35431A PH 26714 A PH26714 A PH 26714A
Authority
PH
Philippines
Prior art keywords
tnf
polypeptide
replaced
leu
pro
Prior art date
Application number
PH35431A
Other languages
English (en)
Inventor
Junichi Yamagishi
Katuhisa Nakata
Hitoshi Kawashima
Hirotada Kotani
Ryuji Furuta
Original Assignee
Dainippon Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dainippon Pharmaceutical Co filed Critical Dainippon Pharmaceutical Co
Publication of PH26714A publication Critical patent/PH26714A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
PH35431A 1986-06-20 1987-07-19 Novel human TNF polypeptide mutants and DNAs encoding said mutants PH26714A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP14557586 1986-06-20

Publications (1)

Publication Number Publication Date
PH26714A true PH26714A (en) 1992-09-15

Family

ID=15388278

Family Applications (1)

Application Number Title Priority Date Filing Date
PH35431A PH26714A (en) 1986-06-20 1987-07-19 Novel human TNF polypeptide mutants and DNAs encoding said mutants

Country Status (10)

Country Link
US (1) US4990455A (de)
EP (1) EP0251037B1 (de)
KR (1) KR880000471A (de)
AT (1) ATE107362T1 (de)
AU (1) AU592196B2 (de)
DE (1) DE3750056T2 (de)
DK (1) DK312387A (de)
HU (1) HU210118B (de)
PH (1) PH26714A (de)
SU (1) SU1762761A3 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5081021A (en) * 1986-02-04 1992-01-14 Mizuno Den Ichi DNA encoding HTNF variants exhibiting enhanced activity
DE3716513A1 (de) * 1987-05-16 1988-11-24 Basf Ag Proteine mit tnf-wirkung
DE3837012A1 (de) * 1988-01-15 1989-07-27 Knoll Ag Verwendung von tnf und lt zur herstellung von arzneimitteln
JPH0797997B2 (ja) * 1988-04-28 1995-10-25 帝人株式会社 新規生理活性ポリペプチド
DE3843534A1 (de) * 1988-12-23 1990-07-12 Basf Ag Neue tnf-polypeptide
DE3922089A1 (de) * 1989-05-09 1990-12-13 Basf Ag Neue proteine und ihre herstellung
US6262239B1 (en) 1989-05-18 2001-07-17 Yeda Research And Development Co., Ltd. TNF receptor-specific antibodies
US6232446B1 (en) 1989-05-18 2001-05-15 Yeda Research And Development Co. Ltd. TNF ligands
EP0897987B1 (de) * 1989-10-24 2001-02-28 Chiron Corporation Sekretion vom mit Gamma-Interferon Signalpeptid gebundenen humänen Protein
US5519119A (en) * 1990-09-21 1996-05-21 Ishihara Sangyo Kaisha Ltd. Muteins of TNF pharmaceutical compositions and a method of making
US5653974A (en) * 1990-10-18 1997-08-05 Board Of Regents,The University Of Texas System Preparation and characterization of liposomal formulations of tumor necrosis factor
CA2055168A1 (en) * 1990-11-21 1992-05-22 Walter Fiers Tnf-muteins
KR970005042B1 (ko) * 1993-02-09 1997-04-11 한일합성섬유공업 주식회사 종양괴사인자-알파 뮤테인
CA2119089A1 (en) * 1993-03-29 1994-09-30 David Banner Tumor necrosis factor muteins
US5888814A (en) * 1994-06-06 1999-03-30 Chiron Corporation Recombinant host cells encoding TNF proteins
US6184344B1 (en) * 1995-05-04 2001-02-06 The Scripps Research Institute Synthesis of proteins by native chemical ligation
US7070771B1 (en) 1996-12-09 2006-07-04 Regents Of The University Of California Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
IL132281A0 (en) 1997-04-15 2001-03-19 Ferring Farma Lab Modified tnf alpha molecules dna encoding such modified tnf alpha molecules and vaccines comprising such modified tnf alpha molecules and dna
US7687461B2 (en) * 2000-03-02 2010-03-30 Xencor, Inc. Treatment of TNF-α related disorders with TNF-α variant proteins
US7056695B2 (en) 2000-03-02 2006-06-06 Xencor TNF-α variants
US20070172449A1 (en) * 2000-03-02 2007-07-26 Xencor, Inc. TNF-alpha VARIANT FORMULATIONS FOR THE TREATMENT OF TNF-alpha RELATED DISORDERS
US7662367B2 (en) 2000-03-02 2010-02-16 Xencor, Inc. Pharmaceutical compositions for the treatment of TNF-α related disorders
US7101974B2 (en) 2000-03-02 2006-09-05 Xencor TNF-αvariants
US7244823B2 (en) 2000-03-02 2007-07-17 Xencor TNF-alpha variants proteins for the treatment of TNF-alpha related disorders
US7446174B2 (en) 2001-03-02 2008-11-04 Xencor, Inc. Protein based TNF-α variants for the treatment of TNF-α related disorders
US7786282B2 (en) * 2001-12-06 2010-08-31 The Regents Of The University Of California Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain
KR100475403B1 (ko) * 2002-05-28 2005-03-15 재단법인서울대학교산학협력재단 반도체 배선용 구리 박막 형성방법
ATE472556T1 (de) * 2002-12-02 2010-07-15 Amgen Fremont Inc Gegen den tumor nekrose faktor gerichtete antikörper und deren verwendungen
WO2014124134A1 (en) 2013-02-07 2014-08-14 The General Hospital Corporation Methods for expansion or depletion of t-regulatory cells

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3723249A (en) * 1970-02-21 1973-03-27 Ajinomoto Kk Method of producing l-arginine by microorganism
JPS6066989A (ja) * 1983-09-24 1985-04-17 Kyowa Hakko Kogyo Co Ltd L−アルギニンの製造法
DE3582183D1 (de) * 1984-03-06 1991-04-25 Dainippon Pharmaceutical Co Dns den menschlichen tumornekrosisfaktor kodierend und das menschliche tumornekronisfaktor-polypeptid.
GR851626B (de) * 1984-07-05 1985-11-26 Genentech Inc
FI862531A0 (fi) * 1984-10-15 1986-06-13 Cetus Corp Tumoernekrosisfaktor.
EP0205038A1 (de) * 1985-05-29 1986-12-17 Suntory Limited Polypeptid, Verfahren zu dessen Herstellung, Mikroorganismus und pharmazeutische Verwendung

Also Published As

Publication number Publication date
EP0251037B1 (de) 1994-06-15
AU7450887A (en) 1988-01-07
SU1762761A3 (ru) 1992-09-15
EP0251037A2 (de) 1988-01-07
KR880000471A (ko) 1988-03-26
US4990455A (en) 1991-02-05
DE3750056T2 (de) 1995-04-06
DK312387A (da) 1987-12-21
HUT46065A (en) 1988-09-28
EP0251037A3 (en) 1988-12-07
AU592196B2 (en) 1990-01-04
HU210118B (en) 1995-02-28
DE3750056D1 (de) 1994-07-21
ATE107362T1 (de) 1994-07-15
DK312387D0 (da) 1987-06-19

Similar Documents

Publication Publication Date Title
US4990455A (en) Novel human TNF polypeptide mutants and DNA's encoding said mutants
CA1341240C (en) Dna encoding human tumor necrosis factor and human tumor necrosis factor polypeptide
US5288852A (en) Human tumor necrosis factor polypeptides
US5494663A (en) Treatment of microbial infection with interleukin 1 polypeptides
JP2644794B2 (ja) 新規な型のコロニー刺激因子―1
JP2708099B2 (ja) エリスロポエチン類縁体
US5247070A (en) N-terminal muteins of tumor necrosis factor
JPH089976A (ja) 腫瘍壊死因子ムテイン
US5043271A (en) DNA encoding rabbit TNE, vector having said DNA inserted thereinto, host transformed with said vector, rabbit TNF polypeptide, and process for production thereof
IL76699A (en) Recombinant human tumor necrosis factor, its production and pharmaceutical compositions containing it
US5519119A (en) Muteins of TNF pharmaceutical compositions and a method of making
EP0477200A1 (de) Reinigung von proteinen mittels ctap-iii schmelzvorgänge
EP0413818B1 (de) Verfahren zur herstellung eines menschlichen "neutrophil chemotactic factor"-polypeptids
EP0470999A1 (de) Verfahren und vektor zur stabilisierung der expression von heterologen proteinen
CA2026453A1 (en) Mutein of acidic fgf, and its production
US5401643A (en) Method of preparing an active human neutrophil chemotactic factor polypeptide
CA2097878C (en) Therapeutic agent for neutropenia
EP0477791B1 (de) Polypeptid
JP2698976B2 (ja) 新規ポリペプチド及びそれをコードするdna
JP2515975B2 (ja) 抗腫瘍作用を有するポリペプチド
CA2051974A1 (en) Polypeptide
JP2678689B2 (ja) 肝炎予防・治療剤
US5290917A (en) Modified polypeptides of IL-1α
CA2051975A1 (en) Polypeptide
WO1990000563A1 (en) A method of treating diseases caused by immunodeficiency states by administering human neutrophil chemotactic factor to human